Burleson & Company, LLC Revance Therapeutics, Inc. Transaction History
Burleson & Company, LLC
- $384 Million
- Q4 2022
A detailed history of Burleson & Company, LLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Burleson & Company, LLC holds 320 shares of RVNC stock, worth $822. This represents 0.0% of its overall portfolio holdings.
Number of Shares
320
Previous 320
-0.0%
Holding current value
$822
Previous $9,000
44.44%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding RVNC
# of Institutions
196Shares Held
81.5MCall Options Held
490KPut Options Held
128K-
Capital World Investors Los Angeles, CA13.9MShares$35.8 Million0.01% of portfolio
-
Black Rock Inc. New York, NY8.57MShares$22 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA6.26MShares$16.1 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.99MShares$15.4 Million0.0% of portfolio
-
Palo Alto Investors LP Palo Alto, CA5.26MShares$13.5 Million1.71% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...